AbbVie struck a licensing and development arrangement with Zelgen Biopharmaceuticals for a clinical‑stage bispecific T‑cell engager targeting DLL3 in China. The deal expands AbbVie’s oncology immunotherapy footprint in the region and gives the company an asset aimed at DLL3‑expressing tumors. The partnership illustrates Big Pharma’s continued strategy of sourcing T‑cell engager programs from regional developers to accelerate localized clinical development and commercialization. The agreement will likely combine AbbVie’s clinical development resources with Zelgen’s regional regulatory knowledge as the program advances through Chinese trials.